Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydroxypropylmethylcellulose + dextran is a combination ophthalmic medication used as artificial tears to relieve symptoms of dry eye and ocular irritation syndromes. The formulation contains two lubricants—hydroxypropylmethylcellulose (also known as hypromellose) and dextran 70—which synergistically form a lubricating, transparent film on the cornea. This film mimics natural tears by providing moisture, stabilizing the precorneal tear film, enhancing corneal wetting through physiological blending with existing tear components, and extending retention time on the ocular surface without increasing viscosity. The combination is indicated for temporary relief of burning and irritation due to dryness of the eye or exposure to wind or sun[1][2][8]. It does not treat underlying disease but provides symptomatic relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hydroxypropylmethylcellulose + dextran.